The screen is designed to meet the needs of routine diagnostic testing, and is fully compatible with the ImmunoCAP automated laboratory systems for straightforward integration into laboratory workflows. It uses a special combination of concentrated and highly specific recombinant antigens to offer excellent sensitivity, with fewer false positives, and exceptional intra- and inter-laboratory reproducibility,
ensuring simple data interpretation.
In addition, the EliA ANA CTD Screen can be used alongside HEp-2 cellular techniques to provide valuable supplementary information in complex cases. By combining virtually all the relevant ANAs for CTDs in a single test, the screen provides clinicians with unambiguous and diagnostically relevant information, reducing the requirement for follow-up testing and improving patient outcomes.
www.phadia.co.uk